Wire · opportunities
Johnson & Johnson scores 1st FDA label expansion for Imaavy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
Johnson & Johnson has secured the first FDA label expansion for Imaavy to treat warm autoimmune hemolytic anemia (wAIHA), a rare and life-threatening disorder. The drug's novel mechanism targets IgG autoantibodies, with clinical trial data showing significant and durable improvements in hemoglobin levels.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a new FDA-approved pathway to treat a rare, underserved autoimmune disorder, opening access to a critical patient set and signalling rising regulatory appetite for novel monoclonal antibodies. Biotech founders targeting autoimmunity should prioritise this mechanism as a benchmark for success.
◆ Coverage
1 source · 25 Aug 2026
◆ Related on Wire
◆ Topics